Central Bank & Trust Co. cut its position in Becton, Dickinson and Company (NYSE:BDX) by 2.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,668 shares of the medical instruments supplier’s stock after selling 209 shares during the period. Central Bank & Trust Co.’s holdings in Becton, Dickinson and were worth $1,496,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of BDX. BlackRock Inc. increased its position in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after buying an additional 796,034 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Becton, Dickinson and during the first quarter worth about $101,993,000. Waverton Investment Management Ltd purchased a new position in shares of Becton, Dickinson and during the second quarter worth about $68,448,000. Finally, Cantillon Capital Management LLC increased its position in shares of Becton, Dickinson and by 30.3% in the first quarter. Cantillon Capital Management LLC now owns 1,344,427 shares of the medical instruments supplier’s stock worth $246,622,000 after buying an additional 312,926 shares in the last quarter. Institutional investors own 75.57% of the company’s stock.
Shares of Becton, Dickinson and Company (NYSE:BDX) traded up 0.36% during mid-day trading on Friday, hitting $198.57. 789,306 shares of the stock traded hands. The stock has a 50-day moving average of $200.05 and a 200 day moving average of $189.42. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63. The stock has a market cap of $45.19 billion, a PE ratio of 57.51 and a beta of 1.05.
Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s quarterly revenue was down 5.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.35 earnings per share. Equities analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.47%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.
COPYRIGHT VIOLATION NOTICE: This story was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://stocknewstimes.com/2017/08/27/central-bank-trust-co-sells-209-shares-of-becton-dickinson-and-company-bdx.html.
A number of research analysts recently issued reports on BDX shares. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price target for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $230.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Becton, Dickinson and presently has an average rating of “Buy” and a consensus price target of $195.79.
In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the sale, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gary M. Cohen sold 15,044 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.43, for a total value of $3,015,268.92. Following the completion of the sale, the insider now directly owns 95,270 shares in the company, valued at approximately $19,094,966.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,605 shares of company stock worth $9,718,986. 1.40% of the stock is currently owned by company insiders.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
